---
schema_version: "secwatch.filing_event.v1"
accession: "0001851734-22-000341"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-24T23:56:06.329417+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# VistaGen terminates President/CSO; PH94B Phase 3 trial completes enrollment

## Summary
- President and CSO H. Ralph Snodgrass terminated effective June 15, 2022.
- Last patient completed protocol in PALISADE-1 Phase 3 trial of PH94B for social anxiety disorder.
- Topline results from PALISADE-1 expected mid-2022; PALISADE-2 topline expected late-2022.
- FDA granted Fast Track designation for PH94B in social anxiety disorder.

## SEC filing metadata
- accession: 0001851734-22-000341
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/0001851734-22-000341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/vtgn20220622_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001851734-22-000341
- JSON: https://secwatch.observer/filing/0001851734-22-000341.json
- Plain text: https://secwatch.observer/filing/0001851734-22-000341.txt

## Key facts
- Executive change
  H. Ralph Snodgrass was terminated as President and Chief Scientific Officer at Vistagen Therapeutics, Inc..
  - Action: terminated
  - Role: President and Chief Scientific Officer
  source text: On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000185173422000341/0001851734-22-000341-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.